Non-Invasive Tests for MASLD/MASH: Moving the Field Forward

Nov 11 2023
Ballroom BC - Hynes Convention Center
4:00 - 5:00 PM EST

Speakers

Alina M. Allen

Department of Gastroenterology and Hepatology, Mayo Clinic

Mary E. McCarthy Rinella

The University of Chicago

Rohit Loomba

University of California, San Diego

Quentin M. Anstee

Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University

Mazen Noureddin

Houston Methodist Hospital, Houston Research Institute

Laurent Castera

Department of Hepatology, Beaujon Hospital, AP-HP, Université Paris Cité, Inserm UMR1149

Arun J. Sanyal

Virginia Commonwealth University

Description

This session delves into the progress in diagnosing At-Risk-MASH, with discussions on the viability of achieving MASH resolution through drug development and the potential of non-invasive tests (NITs) for outcome prediction. The session also explores a Phase 3 design that eliminates the need for liver biopsy. The event wraps up with a panel discussion featuring experts from various fields, offering diverse perspectives on the topics discussed.

Objectives

  • Grasp the latest developments in diagnosing and managing At-Risk-MASH, including the potential for MASH resolution through drug advancements and the use of non-invasive tests (NITs) for outcome prediction.
  • Explore the practical implications of a liver biopsy-free Phase 3 design in MASH research, understanding its advantages and potential obstacles